All News
H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Read Article
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Read Article
Methotrexate in OA (10.20.2023)
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Read Article
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
Read Article
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu
Dr. Rachel Tate ( View Tweet)
How can we maximise digital health to improve outcomes. Come and visit my poster session today and it will be good to meet IRL. I’m presenting poster #0507 using digital e-PROMs to measure disease activity in psoriatic arthritis #digital Abst #0507 #ACR23 @RheumNow https://t.co/R9LX8H9X0E
Dr. Antoni Chan ( View Tweet)
#ACR23 Abs 0484 found higher hs-CRP levels helped identify PsO pts at high risk of future development of PsA. Unclear timeline, but this may help to early ID referrals to rheum. https://t.co/4JRsI6iEgI @rheumnow https://t.co/sXNwyL87Ud
Dr. Rachel Tate ( View Tweet)
Pain, itch, and fatigue associated with decreased work productivity/impairment in PsA and PsO pts. #ACR23 considerations for treatment for these pts should include these factors. Abs #0488 https://t.co/mLG5ohFopQ @rheumnow https://t.co/8ANL4pcxM2
Dr. Rachel Tate ( View Tweet)
Different plant products
We need more RCTs
Cohort studies have a lot of attrition
Survey data shows increased utilization
#ACR23 @RheumNow https://t.co/H2pOEJ99Qh
Bella Mehta bella_mehta ( View Tweet)
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w
Dr. John Cush RheumNow ( View Tweet)
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/7juI2Dghjh https://t.co/SxCaJgTmeQ
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt
Dr. John Cush RheumNow ( View Tweet)
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/GYKPSaYWhU https://t.co/YYwaiQd5mJ
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw
Dr. John Cush RheumNow ( View Tweet)
